首页> 外文期刊>Expert opinion on biological therapy >Carriers for the delivery of a vaccine against respiratory syncytial virus.
【24h】

Carriers for the delivery of a vaccine against respiratory syncytial virus.

机译:运送抗呼吸道合胞病毒疫苗的载体。

获取原文
获取原文并翻译 | 示例
           

摘要

Respiratory syncytial virus (RSV) is a major cause of bronchiolitis and pneumonia in young children and the elderly. Despite its clinical importance, there is no licensed vaccine available at present. Vaccine development has been hampered by observations of increased pathology after RSV infection in infants vaccinated with formalin-inactivated RSV; incomplete immunity following natural infection; and the need to be effective during the neonatal period when levels of maternal antibody are high. Four categories of RSV vaccine carriers--live-attenuated RSVs, recombinant vectors expressing the protective antigens of RSV, DNA vaccines and subunit vaccines--have been evaluated in animal models and/or clinical trials. So far, studies with live-attenuated virus vaccines highlight the need to improve immunogenicity whilst maintaining a suitable level of attenuation. Studies with recombinant vectors, DNA and subunit vaccines illustrate the pivotal nature of the vaccine carrier in determining the balance between immune-mediated protection against infection and the induction of immune-mediated pulmonary pathology.
机译:呼吸道合胞病毒(RSV)是导致幼儿和老年人支气管炎和肺炎的主要原因。尽管具有临床重要性,但目前尚无许可的疫苗。观察到用福尔马林灭活的RSV疫苗接种的婴儿在RSV感染后病理增加,从而阻碍了疫苗的发展。自然感染后免疫力不完全;并且在母体抗体水平高的新生儿期需要有效。已在动物模型和/或临床试验中评估了四类RSV疫苗载体-减毒活RSV,表达RSV保护性抗原的重组载体,DNA疫苗和亚单位疫苗。迄今为止,减毒活疫苗的研究强调需要在保持适当的减毒水平的同时提高免疫原性。重组载体,DNA和亚单位疫苗的研究表明,疫苗载体在确定免疫介导的抗感染保护与诱导免疫介导的肺部病理之间的平衡方面具有关键性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号